Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers

Phase 1 Completed 30 enrolled Chong Kun Dang Pharmaceutical

RandomizedCrossoverOpen-labelTreatment

This study is a randomized, open-label, single dose, crossover study to evaluate the pharmacokinetics and safety of CKD-383 in healthy volunteers

Evaluation	Drug	Modality	Dose	Route
Subject	CKD-383	Unknown	—	Oral
Subject	D150	Unknown	—	Oral
Subject	D745	Unknown	—	Oral
Subject	Lobeglitazone	Small molecule	—	Oral